Mutating chikunguny a virus non-structural proteinproduces potent live-attenuated vaccine candidate

Chan, Yi-Hao, Teo, Teck-Hui, Utt, Age, Tan, Jeslin JL, Amrun, Siti Naqiah, Abu Bakar, Farhana, Yee, Wearn-Xin, Becht, Etienne, Lee, Cheryl Yi-Pin, Lee, Bernett
et al (show 6 more authors) (2019) Mutating chikunguny a virus non-structural proteinproduces potent live-attenuated vaccine candidate. EMBO Molecular Medicine, 11 (6). e10092-.

Access the full-text of this item by clicking on the Open Access link.


Currently, there are no commercially available live‐attenuated vaccines against chikungunya virus (CHIKV ). Here, CHIKV s with mutations in non‐structural proteins (nsPs) were investigated for their suitability as attenuated CHIKV vaccines. R532H mutation in nsP1 caused reduced infectivity in mouse tail fibroblasts but an enhanced type‐I IFN response compared to WT ‐CHIKV . Adult mice infected with this nsP‐mutant exhibited a mild joint phenotype with low‐level viremia that rapidly cleared. Mechanistically, ingenuity pathway analyses revealed a tilt in the anti‐inflammatory IL ‐10 versus pro‐inflammatory IL ‐1β and IL ‐18 balance during CHIKV nsP‐mutant infection that modified acute antiviral and cell signaling canonical pathways. Challenging CHIKV nsP‐mutant‐infected mice with WT ‐CHIKV or the closely related O'nyong‐nyong virus resulted in no detectable viremia, observable joint inflammation, or damage. Challenged mice showed high antibody titers with efficient neutralizing capacity, indicative of immunological memory. Manipulating molecular processes that govern CHIKV replication could lead to plausible vaccine candidates against alphavirus infection.

Item Type: Article
Uncontrolled Keywords: chikungunya, live-attenuated vaccine, mutation, neutralizing antibody, non-structural protein
Depositing User: Symplectic Admin
Date Deposited: 22 May 2019 14:11
Last Modified: 19 Jan 2023 00:43
DOI: 10.15252/emmm.201810092
Open Access URL:
Related URLs: